|
Epicept Corporation - Company Profile Snapshot
| Company Profile: |
Epicept Corporation |
| Ticker: |
EPCT |
| Exchanges: |
NAS |
| 2008 Sales: |
265,000 |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Medical Services |
| Country: |
UNITED STATES |
| Employees: |
21 |
Business Description
Epicept Corporation. The Group's principal activity is to develop and commercialize pharmaceutical products for the treatment of cancer and pain. The lead product is Ceplene(R), which when used concomitantly with interleukin-2 or IL-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia or AML for adult patients who are in their first complete remission. In addition to Ceplene(R), it has two oncology compounds and a pain product candidate for the treatment of peripheral neuropathies in clinical development. Its cancer portfolio includes Crinobulin, or EPC2407, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with solid tumors and lymphomas. Its late-stage pain product candidate, EpiCeptTM NP-1 Cream is a prescription topical analgesic cream designed to provide effective long-term relief of pain associated with peripheral neuropathies. It operates in the Unites States and Germany.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
